The National Institute of Health and Care Excellence (NICE) has recommended the use of ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 2 or 3 prior treatments.
This decision is based upon data from the ongoing Phase III TOURMALINE-MM1 trial which is comparing ixazomib, lenalidomide and dexamethasone to lenalidomide and dexamethasone alone. The results from the second interim analysis show that the addition of ixazomib significantly improved progression-free survival in patients, however the impact on overall survival is not yet clear. Therefore, until further data is collected, this treatment will only be available through the CDF.